REPRODUCTIVE HORMONES & THE FERTILITY AXIS / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to kisspeptin and PT-141.
What is kisspeptin?
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene. The 145-amino-acid precursor is cleaved into several shorter bioactive forms — kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10 — that all share a conserved Arg-Phe-amide motif required for binding to their receptor, KISS1R (GPR54). It is produced in the hypothalamus and acts as the primary activator of GnRH neurons, sitting upstream of the entire reproductive hormone axis [7]. It is investigational — no formulation is approved by any regulator for any indication as of 2025 [2]. Not a supplement; not for self-administration.
What does kisspeptin do?
Kisspeptin activates KISS1R on GnRH neurons in the hypothalamus, triggering a phospholipase C–calcium cascade that depolarizes the neuron and causes it to release GnRH [6]. GnRH reaches the pituitary and drives out LH and FSH, which then stimulate the gonads to produce testosterone or estrogen. In plain terms: kisspeptin tells the brain's own reproductive hormone system to turn on. It has been shown to restore LH pulsatility in women with hypothalamic amenorrhea [4], stimulate LH and testosterone in men [5], and trigger oocyte maturation in IVF protocols [3].
Does kisspeptin increase testosterone?
In research settings, yes — as a downstream consequence of activating the HPG axis. In healthy men, continuous intravenous kisspeptin-10 infusion at 4 µg/kg/h raised serum testosterone from 16.6 to 24.0 nmol/L, alongside increases in LH pulse frequency and mean LH [5]. These are single study findings in a controlled research setting; they are measurements, not treatment protocols, and they come with the caveat that tachyphylaxis develops with sustained or repeated activation of KISS1R [4]. No regulatory-approved dose or protocol exists for this purpose.
How much does kisspeptin increase testosterone?
In the one published study that measured it directly, the highest kisspeptin-10 infusion rate (4 µg/kg/h intravenously in healthy men) raised serum testosterone from 16.6 to 24.0 nmol/L — roughly a 45% increase during the infusion [5]. This is a research-setting finding in a small group of healthy male volunteers. It is not a generalizable dose-response relationship, and it is not a recommendation. The effect of repeated dosing would be reduced by KISS1R desensitization (tachyphylaxis), which the same research literature documents [4].
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is a melanocortin receptor agonist, primarily targeting MC4R in the brain's hypothalamic and limbic circuits. Bremelanotide was approved by the US FDA in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [12]. Research-chemical "PT-141" sold outside the pharmaceutical system is not an approved product and is for laboratory research only.
What is PT-141 peptide?
PT-141 is a cyclic peptide — unlike linear chains, its seven amino acids are joined in a ring by a lactam bridge between Asp and Lys side chains. This ring structure makes it more resistant to breakdown than many linear peptides. It is a metabolic relative of Melanotan 2 but chemically distinct — different C-terminal group and different receptor-selectivity profile. It activates MC4R and MC3R but has less activity at MC1R (the pigmentation receptor) than Melanotan 2, which is why it does not cause the broad tanning effect of that compound (though some pigmentation is still possible with frequent dosing) [12].
What does the PT-141 peptide do?
PT-141 (bremelanotide) activates melanocortin receptors — primarily MC4R — in the hypothalamus and limbic system. This is thought to engage dopaminergic pathways governing sexual motivation and desire, producing the central sensation of wanting sex rather than a peripheral vascular or hormonal effect [9]. In two Phase 3 RCTs of premenopausal women with HSDD, it significantly increased sexual desire scores and reduced desire-related distress versus placebo over 24 weeks [10]. A neuroimaging study showed it altered brain processing of erotic stimuli — enhanced amygdala-insula connectivity — alongside increased self-reported desire [9].
What is PT-141 used for?
Officially: bremelanotide is approved in the US for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — specifically women who find their low sexual desire distressing and who have not just lost desire because of relationship issues or a medical condition that should be treated first [12]. Off-label: it is investigated and used in men for sexual desire and erectile function, and in postmenopausal women, but these uses are outside the approved indication. Research-chemical use is outside all approved frameworks.
What is the difference between kisspeptin and PT-141?
They work on entirely different systems. Kisspeptin acts on the reproductive hormone axis — activating GnRH neurons to drive LH, FSH, and gonadal sex-steroid production [7]. Its connection to sexual desire runs through downstream hormones. PT-141 bypasses the hormone axis and acts directly on central melanocortin circuits in the brain that drive sexual desire and motivation [9]. Kisspeptin is investigational across all uses [2]; PT-141 has an approved indication for HSDD in premenopausal women [12]. See the compare page for a full side-by-side.
Does kisspeptin affect libido or sexual desire?
Directly studied? Not in a controlled trial. Plausible via mechanism? Yes — kisspeptin drives testosterone and estrogen production [5], and sex steroids are established contributors to libido and sexual desire. Community anecdote includes reports of heightened sexual interest following kisspeptin administration, but these are sparse, not controlled, and should be treated as anecdotal signals, not clinical evidence. The research was designed to study LH pulsatility and fertility endpoints, not desire per se. PT-141 is the compound on this desk with a formal controlled-trial record in sexual desire [10].
Is PT-141 safe for men?
PT-141 in men is off-label — it has not been approved for any male indication, and controlled safety studies in men are not part of the Phase 3 program that led to approval [12]. Early Phase 2 data suggested possible benefit in erectile function, but controlled male efficacy trials were not completed. The safety signals documented in women (transient blood-pressure rise, nausea, headache, flushing, and possible hyperpigmentation with frequent use [11][12]) are pharmacologically expected and would apply to men through the same mechanisms. Anyone with uncontrolled hypertension or cardiovascular disease faces the most direct documented risk from the blood-pressure effect. Off-label use is outside the studied framework.
What are the main side effects of PT-141?
In the long-term clinical trial, the most common drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [11]. The approved label also documents a transient blood-pressure increase after dosing (contraindicated in uncontrolled hypertension or cardiovascular disease) and the potential for hyperpigmentation of the face, gums, and breasts with frequent dosing [12]. Community reports broadly align: nausea is described as the dominant complaint, often worst on the first use and easing with repeated lower-frequency dosing. Some users report no effect at all alongside side effects — non-response is a genuine outcome.
Why does kisspeptin cause tachyphylaxis?
Tachyphylaxis — a fading response to repeated stimulation — is a property of KISS1R itself. When KISS1R is activated continuously or at high frequency, it undergoes receptor downregulation (internalization and reduced surface expression), reducing the next response to the same stimulus. In a clinical infusion study, the highest continuous dose of kisspeptin-54 produced tachyphylaxis within the infusion, and the LH response fell over time [4]. The same pattern is described by self-experimenters using repeated dosing. The implication is that intermittent, spaced exposure preserves receptor sensitivity in a way that continuous dosing does not.